Akèy › Lukemi miyomonositè kwonik › Texas › Houston
Etid klinik pou Lukemi miyomonositè kwonik nan Houston, TX
16 etid pou Lukemi miyomonositè kwonik ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center, Houston
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Ap rekriteFaz 2Volontè an sante akeyi
- MD Anderson Cancer Center, Houston
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Ap rekriteFaz 2/3Volontè an sante akeyi
- M D Anderson Cancer Center, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Ap rekriteFaz 1/2
- M D Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Ap rekriteFaz 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Ap rekriteFaz 1
- M D Anderson Cancer Center, Houston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Ap rekriteFaz 2/3
- MD Anderson Cancer Center, Houston
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Ap rekriteFaz 1/2
- M D Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Ap rekriteFaz 2
- MD Anderson, Houston
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Etid Lukemi miyomonositè kwonik nan lòt vil
- Seattle, WA10 etid
- Boston, MA7 etid
- New York City, NY6 etid
- Baldwin Park, CA6 etid
- Mountain View, CA6 etid
- Rochester, MN6 etid
- Durham, NC5 etid
- Miami, FL4 etid
- Birmingham, AL4 etid
- Tampa, FL4 etid
- Atlanta, GA4 etid
- Columbus, OH4 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt68 etid
- Kansè pankreyas61 etid
- Melanom59 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.